166 related articles for article (PubMed ID: 18221048)
1. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?
Santini D; Schiavon G; Angeletti S; Vincenzi B; Gasparro S; Grilli C; La Cesa A; Virzí V; Leoni V; Budillon A; Addeo SR; Caraglia M; Dicuonzo G; Tonini G
Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):383-96. PubMed ID: 18221048
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates: preclinical review.
Green JR
Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
6. The molecular basis of bisphosphonate activity: a preclinical perspective.
Green J; Clézardin P
Semin Oncol; 2010 Jun; 37 Suppl 1():S3-11. PubMed ID: 20682369
[TBL] [Abstract][Full Text] [Related]
7. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.
Santini D; Virzi V; Fratto ME; Bertoldo F; Sabbatini R; Berardi R; Calipari N; Ottaviani D; Ibrahim T
Curr Cancer Drug Targets; 2010 Feb; 10(1):46-54. PubMed ID: 20088792
[TBL] [Abstract][Full Text] [Related]
8. New role for an established drug? Bisphosphonates as potential anticancer agents.
Koul HK; Koul S; Meacham RB
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):111-9. PubMed ID: 21876554
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
10. The critical role of bisphosphonates to target bone cancer metastasis: an overview.
Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK
J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates in cancer therapy.
Stresing V; Daubiné F; Benzaid I; Mönkkönen H; Clézardin P
Cancer Lett; 2007 Nov; 257(1):16-35. PubMed ID: 17697748
[TBL] [Abstract][Full Text] [Related]
12. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
Reinholz GG; Getz B; Sanders ES; Karpeisky MY; Padyukova NSh; Mikhailov SN; Ingle JN; Spelsberg TC
Breast Cancer Res Treat; 2002 Feb; 71(3):257-68. PubMed ID: 12002344
[TBL] [Abstract][Full Text] [Related]
13. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.
Marra M; Abbruzzese A; Addeo R; Del Prete S; Tassone P; Tonini G; Tagliaferri P; Santini D; Caraglia M
Curr Cancer Drug Targets; 2009 Nov; 9(7):791-800. PubMed ID: 20025567
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis I; Kousidou OCh; Karamanos NK
In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antitumor effects of bisphosphonates.
Clézardin P; Fournier P; Boissier S; Peyruchaud O
Curr Med Chem; 2003 Jan; 10(2):173-80. PubMed ID: 12570716
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates as anticancer therapy for early breast cancer.
Mahtani R; Jahanzeb M
Clin Breast Cancer; 2010 Oct; 10(5):359-66. PubMed ID: 20920980
[TBL] [Abstract][Full Text] [Related]
17. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects and anticancer applications of bisphosphonates.
Morgan G; Lipton A
Semin Oncol; 2010 Oct; 37 Suppl 2():S30-40. PubMed ID: 21111246
[TBL] [Abstract][Full Text] [Related]
19. Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment.
La-Beck NM; Liu X; Shmeeda H; Shudde C; Gabizon AA
Semin Cancer Biol; 2021 Jan; 68():175-185. PubMed ID: 31874280
[TBL] [Abstract][Full Text] [Related]
20. The role of bisphosphonates in breast and prostate cancers.
Brown JE; Neville-Webbe H; Coleman RE
Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]